Bacterin International Holdings, Inc.
Reconciliation of Net (Loss) Income From Operations to EBITDA
(Unaudited)Three Months Ended June 30,Six Months Ended June 30,2012201120122011 Net Loss from ops(347,357)(279,997)(1,620,520)(2,216,296) Depreciation95,20662,533214,280115,205 Allocated depreciation94,48694,486188,972188,972 Stock option comp190,055-385,587381,199 Non-cash stock comp(24,069)157,485304,184388,4758,32134,507(527,497)(1,142,445)
About Bacterin International HoldingsBacterin International Holdings, Inc. (NYSE MKT: BONE) develops, manufactures and markets biologics products to domestic and international markets. Bacterin's proprietary methods optimize the growth factors in human allografts to create the ideal stem cell scaffold to promote bone, subchondral repair and dermal growth. These products are used in a variety of applications including enhancing fusion in spine surgery, relief of back pain, promotion of bone growth in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral repair in knee and other joint surgeries.
Bacterin's Medical Device division develops, employs, and licenses bioactive coatings for various medical device applications. Bacterin's strategic coating initiatives include antimicrobial coatings designed to inhibit biofilm formation and microbial contamination. For further information, please visit www.bacterin.com.
Important Cautions Regarding Forward-looking StatementsThis news release contains certain disclosures that may be deemed forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to significant risks and uncertainties. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or
|SOURCE Bacterin International Holdings, Inc.|
Copyright©2012 PR Newswire.
All rights reserved